|Articles|November 18, 2003
Anecortave acetate found to safe, effective for inhibiting CNV growthin AMD patients
Anecortave acetate (Retaane), a potent angiostatic agent, has been shownto be safe and superior to placebo in reducing loss of vision from baseline,avoiding severe vision loss, and inhibiting the growth of CNV membranesin patients with age-related macular degeneration (AMD), reported JasonS. Slakter, MD, who spoke during the American Academy of Ophthalmology annualmeeting.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Nanoscope secures new US patent for Multi-Characteristic Opsin (MCO) technology platform
2
Glaucoma innovation: Eight themes to watch in 2026
3
FDA grants Fast Track Designation to Complement Therapeutics’ CTx001 for geographic atrophy
4
First patient treated in dose-expansion portion of SpliceBio's phase 1/2 ASTRA clinical trial
5








































